ClinicalTrials.gg
RecruitingNCT06139107Updated Nov 14, 2025

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

A Phase 1 interventional study of Abemaciclib and Letrozole in Breast Cancer, sponsored by Mridula George, MD. Recruiting at 4 sites in United States. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by Mridula George, MD · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Planned enrollment
49th of 55
15 · median 120
Started
2024
with 4 others
Phase 1
6 of 55
2 open now
Primary completion
2026-09
later than 11 of 33 live
Registered
41st of 55
by date

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 49th largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 11 of the 33 other live ones, and was the 41st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 60 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on their safety and tolerability. The hypothesis is that the combination therapy will be well-tolerated, providing valuable insights into its effectiveness for future clinical applications.

Read the detailed description

In this phase 1b study, researchers will conduct a comprehensive investigation into the concurrent administration of pre-operative radiation therapy and CDK4/6 inhibitors in a carefully selected participant population diagnosed with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to elucidate the safety and feasibility of this combination therapy. Participants will undergo rigorous evaluation and monitoring to assess the potential synergistic effects and adverse reactions resulting from the simultaneous use of radiation and CDK4/6 inhibitors. Detailed clinical assessments, imaging studies, and laboratory analyses will be performed to monitor treatment response and any associated side effects.

The study hypothesizes that this combination therapy will be well-tolerated, paving the way for further investigations into its efficacy. By closely examining the outcomes and tolerability of this treatment approach, researchers aim to contribute valuable data to the understanding of novel therapeutic strategies for HR+/HER2- breast cancer. The detailed analysis of participant responses and safety profiles in this study will provide crucial insights for optimizing future clinical interventions and improving outcomes for individuals diagnosed with this specific breast cancer subtype.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Pre-op radiation
  • CDK4/6 inhibitors
  • Positive/HER2 negative (HR+/HER2-) breast cancer
  • Abemaciclib
  • Combination of abemaciclib and radiation
  • Post-menopausal women
  • Node-negative hormone-receptor (HR) positive/ human epidermal growth factor receptor 2 (HER2)
  • Negative breast cancers
  • Phase 1b
  • Letrozole and abemaciclib
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed diagnosis of invasive (ductal, lobular or mixed histology), Clinically inapparent tumor that is not palpable. (cT1-T2N0)disease. Minimum tumor size of 1.5 cm
  • Expression of ER or progesterone receptors (PR)and negative expression of per American Society of Clinical Oncology, (ASCO) Common Alerting Protocol (CAP) guidelines
  • Oncotype diagnosis (DX) Breast Recurrence score of less than 25 on core specimen
  • status defined:
  • age \<60 with amenorrhea for at least 12 months in the absence of prior chemotherapy, tamoxifen, toremifene, or ovarian suppression and estradiol and FSH (follicle stimulating hormone) in postmenopausal range.
  • No clinical suspicion of disease
  • (ECOG) performance status of follicle stimulating hormone (PFS) ≤2
  • Eligible to undergo surgery, either lumpectomy or mastectomy for local treatment of the breast cancer
  • Able to swallow oral medications
  • Adequate organ function for all of the following:

Absolute Neutrophil (ANC) >1.5 x 10/L >100 x 10/L >8 g/dL - May receive erythrocyte transfusions to achieve this level Total \<1.5 x (ULN) (ATL) and Aspartate Aminotransferase (AST) \<3 x ULN

  • HR positive/HER2 -negative breast cancers are allowed as long as no other exclusions exist

Exclusion criteria

Exclusion Criteria:

  • History of ipsilateral breast cancer
  • Prior treatment with CDK4/6 inhibitors or aromatase inhibitors
  • History of chest wall or ipsilateral breast radiation
  • Inflammatory breast cancer
  • Needs chemotherapy
  • Presence of distant disease
  • for surgery
  • Uncontrolled hypertension (systolic blood pressure >190 mm Hg or diastolic blood pressure >100 mm Hg)
  • Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study
  • \< 12 weeks
  • History of allergy or to any of the study drugs
  • Any significant medical condition, laboratory abnormality, or psychiatric illness
  • Serious and/or uncontrolled preexisting medical condition
  • Has had major surgery within 14 days prior to enrollment
  • Has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to enrollment, or is currently enrolled in any other type of medical research
  • Has active systemic bacterial infection
  • Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Combined Pre-Operative Therapy with Abemaciclib, Letrozole, and Radiation in HR+/HER2- Breast Cancer

    Part A: * 28-day treatment cycle based on abemaciclib * Abemaciclib 150mg BID (twice a day). * Letrozole 2.5mg daily and Abemaciclib 150mg twice a day for three cycles prior to undergoing radiation therapy. * On-treatment biopsy conducted between cycle 3, day 16, and cycle 4, day 1. * This occurs two weeks prior to transitioning to Part B. Dose Level 0 150mg Twice daily with at least 6 hours between doses Dose Level 1 100mg Twice daily with at least 6 hours between doses Dose Level 2 50mg Twice daily with at least 6 hours between doses Part B: * Continue treatment from Part A, 28-day cycle based on abemaciclib. * Abemaciclib 150mg BID (twice a day) with letrozole 2.5mg daily. * Part B focuses on the administration of radiation therapy following the three cycles of combined abemaciclib and letrozole. * Targeted radiation treatment. Part C: * Two cycles of abemaciclib, 150mg twice a day. * Letrozole 2.5mg daily. Part D: Surgery

    Drug: Abemaciclib · Drug: Letrozole

Interventions

  • 150mg twice a day for 3 cycles prior to radiation.

    Also known as: CDK4/6 Inhibitor Therapy.

  • Letrozole 2.5mg daily

    Also known as: Aromatase Inhibitor Therapy.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of the combination of abemaciclib and radiation as assessed by adverse events (AEs). Using Common Terminology Criteria for Adverse Events (CTCAE v5.0)

    The outcome measure aims to characterize the safety and toxicity profile of the study treatment by assessing the occurrence and severity of adverse events (AEs) as measured using the CTCAE v.5. The CTCAE v.5 utilizes a standardized grading scale to assess the severity of adverse events. The scale consists of grades ranging from 1 to 5, with each grade corresponding to a specific level of severity. The grades are: Grade 1 Mild Event is asymptomatic or mild, requiring minimal or no medical intervention. Grade 2 Moderate Event minimal to moderate interference with daily activities, and some medical intervention. Grade 3 Severe Event causes significant interference with daily activities, and medical intervention or treatment is required. Grade 4 Life-threatening or disabling Event poses immediate risk to life or function, requiring urgent medical intervention or treatment. Grade 5 Death Event results in death related to the adverse event.

    Time frame: From baseline, every six months, to five years

Secondary outcomes

  1. Clinical efficacy of the study treatment regimen measured by Rates of Residual Cancer Burden (RCB).

    Rate of post-operative complications will be measured by RCB. as defined below: RCB-0: No residual cancer in the breast RCB-I: Minimal residual cancer (only small clusters or single cells) RCB-II: Moderate residual cancer (larger or more numerous groups of cells) RCB-III: Extensive residual cancer (large nests, sheets, or extensive involvement of breast tissue) RCB Index Calculation: The RCB index is calculated based on these components. Scores to each component (e.g., size, lymph node involvement, Ki67 index, invasive vs. in situ disease) and then determine the overall RCB index score for a participants. Interpretation: RCB-0: Pathologic complete response, indicating no visible cancer in the breast after treatment. RCB-I, RCB-II, RCB-III: Increasing levels of residual cancer burden, with RCB-III representing the highest burden.

    Time frame: From baseline, every six months, to five years

  2. Rate of post-operative complications measured by descriptive statistics

    The utilization of descriptive statistics to present a comprehensive overview of the post-operative complications. This includes the calculation of means, medians, standard deviations, to understanding of the range and severity of complications observed in the participants cohort.

    Time frame: From baseline, every six months, to five years

  3. Rate of breast-conserving surgery measured with with a 95% confidence interval for proportions

    The evaluation of the Rate of Breast-Conserving Surgery, assessed as a proportion with a 95% confidence interval, provides an understanding of the prevalence of breast-conserving procedures within the studied population. This approach employs rigorous statistical analysis to calculate the proportion of participants who underwent breast-conserving surgery, accompanied by a confidence interval that enhances the reliability of the findings. The calculated proportion signifies the fraction of participants opting for breast-conserving surgery among the total number of individuals included in the study. This proportion serves as a crucial metric, indicating the preference and acceptance of less invasive surgical methods among participants diagnosed with breast cancer. The confidence interval serves as a measure of the precision and reliability of the calculated proportion.

    Time frame: From baseline, every six months, to five years

  4. Rates of residual cancer burden (RCB) as a proportion with 95% confidence interval

    The analysis of Rates of Residual Cancer Burden as a proportion, accompanied by a 95% confidence interval, offers a precise and reliable understanding of the residual cancer burden within the studied population. This approach involves calculating the proportion of participants with different levels of residual cancer burden (such as RCB-0, RCB-I, RCB-II, RCB-III) among the total number of participants evaluated. The 95% confidence interval provides a range in which the true proportion of participants with each level of residual cancer burden is likely to fall, enhancing the statistical precision and reliability of the findings.

    Time frame: From baseline, every six months, to five years

  5. Two year invasive disease-free survival (DFS) rate

    DFS rate is calculated by dividing the number of participants who have not experienced disease recurrence or progression within a specified timeframe by the total number of participants enrolled in the clinical trial. DFS Rate (%) = (Number of participants with no disease recurrence or progression / Total number of participants enrolled) × 100 A higher DFS rate indicates a greater efficacy of liposomal doxorubicin and carboplatin as an adjuvant treatment, suggesting their ability to delay or prevent disease recurrence or progression in participants. A higher DFS rate implies a better prognosis and improved disease control in the adjuvant setting. Kaplan-Meier survival curve will be calculated and the rate and 95% confidence interval for disease-free survival calculated.

    Time frame: From baseline, every six months, to five years

Other outcomes

  1. Changes to DNA repair mechanism measured by Harvard/NSABP/Radiation Therapy Oncology Group (RTOG) breast Cosmesis scale

    Harvard/NSABP/RTOG breast Cosmesis scale: 1. Excellent - There is minimal or no difference in the size or shape of the treated breast. The breast feels the same or slightly different. There may be thickening, scar tissue, or fluid accumulation within the breast. 2. Good - Slight difference in the size or the shape of the treated breast as compared to the opposite breast or the original appearance of the treated breast. The thickening or scaring tissue within the breast causes only a mild change in the shape or size. 3. Fair - Obvious difference in the size and shape of the treated breast. Involves one-quarter or less of the breast. There can be moderate thickening or scar tissue of the skin and the breast, may be obvious color change. 4. Poor - Change in the appearance of the treated breast involving more than one-quarter of the breast tissue. Skin changes may be obvious and detract from the appearance of the breast. Sever scaring and thickening of the breast.

    Time frame: From baseline, every six months, to five years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 25 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Aug 22, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2032
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06139107
Lead sponsor
Mridula George, MD
Responsible party
Mridula George, MD (Assistant Professor of Medicine, Rutgers, The State University of New Jersey) — Sponsor-investigator
First posted
Nov 18, 2023
Start date
Aug 22, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2032 (estimated)
Last update
Nov 14, 2025

Study contacts

Mridula A George, MD
Contact
mridula@cinj.rutgers.edu
732-235-9081
Mridula A George, MD
Contact
mridula@cinj.rutgers.edu
Mridula
Mridula A George, MD
principal investigator · Cancer Institute of New Jersey Rutgers

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Letrozole

Start the discussion